Elite Pharmaceuticals (ELTP) Price & Analysis

Q: What was Elite Pharmaceuticals’s price range in the past 12 months?

Elite Pharmaceuticals lowest stock price was $0.27 and its highest was $0.82 in the past 12 months.

Q: What is Elite Pharmaceuticals’s market cap?

Elite Pharmaceuticals’s market cap is $653.39M.

Q: When is Elite Pharmaceuticals’s upcoming earnings report date?

Elite Pharmaceuticals’s upcoming earnings report date is Feb 16, 2026 which is in 72 days.

Q: How were Elite Pharmaceuticals’s earnings last quarter?

Elite Pharmaceuticals released its earnings results on Nov 14, 2025. The company reported $0.005 earnings per share for the quarter, beating the consensus estimate of N/A by $0.005.

Q: Is Elite Pharmaceuticals overvalued?

According to Wall Street analysts Elite Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Elite Pharmaceuticals pay dividends?

Elite Pharmaceuticals does not currently pay dividends.

Q: What is Elite Pharmaceuticals’s EPS estimate?

Elite Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Elite Pharmaceuticals have?

Elite Pharmaceuticals has 1,070,963,100 shares outstanding.

Q: What happened to Elite Pharmaceuticals’s price movement after its last earnings report?

Elite Pharmaceuticals reported an EPS of $0.005 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -14.706%.

Q: Which hedge fund is a major shareholder of Elite Pharmaceuticals?

Currently, no hedge funds are holding shares in ELTP

Compare

367 Followers

ELTP Stock Chart & Stats

$0.52

>-$0.01(-0.02%)

At close: Jan 08 4:00 PM EST

$0.52

>-$0.01(-0.02%)

Day’s Range― - ―

52-Week Range$0.27 - $0.82

Previous CloseN/A

Volume475.03K

Average Volume (3M)951.20K

Market Cap

$653.39M

Enterprise Value$464.34M

Total Cash (Recent Filing)$26.62M

Total Debt (Recent Filing)$3.32M

Price to Earnings (P/E)―

Beta1.55

Next Earnings

Feb 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding1,070,963,100

10 Day Avg. Volume753,540

30 Day Avg. Volume951,200

Financial Highlights & Ratios

PEG Ratio0.90

Price to Book (P/B)8.68

Price to Sales (P/S)5.53

P/FCF Ratio94.25

Enterprise Value/Market Cap0.71

Enterprise Value/Revenue3.78

Enterprise Value/Gross Profit7.18

Enterprise Value/Ebitda17.75

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Elite Pharmaceuticals News

Elite Pharmaceuticals’ Earnings Call Highlights Robust Growth Amid Challenges

Elite Pharmaceuticals (($ELTP)) has held its Q2 earnings call. Read on for the main highlights of the call....

18d ago

ELTP

Elite Pharmaceuticals Reports Strong Financial Turnaround

Elite Pharmaceuticals ( ($ELTP) ) has released its Q2 earnings. Here is a breakdown of the information Elite...

19d ago

ELTP

Elite Pharmaceuticals Reports 92% Revenue Growth in Q2

The latest announcement is out from Elite Pharmaceuticals ( ($ELTP) ). Elite Pharmaceuticals, Inc. reported significant financial growth...

22d ago

ELTP

Elite Pharmaceuticals Gains FDA Approval for Generic Drug

Elite Pharmaceuticals ( ($ELTP) ) just unveiled an update. On November 12, 2025, Elite Pharmaceuticals announced it received...

24d ago

ELTP

Elite Pharmaceuticals to Release Q2 2026 Results Soon

Elite Pharmaceuticals ( ($ELTP) ) has provided an announcement. Elite Pharmaceuticals announced that it will release its second...

26d ago

ELTP

Elite Pharmaceuticals Reports Strong Q1 Growth

Elite Pharmaceuticals ( ($ELTP) ) has released its Q1 earnings. Here is a breakdown of the information Elite...

4M ago

ELTP

Elite Pharmaceuticals Reports 114% Revenue Growth in Q1 2026

An announcement from Elite Pharmaceuticals ( ($ELTP) ) is now available. Elite Pharmaceuticals reported significant financial growth for...

4M ago

ELTP

Elite Pharmaceuticals to Announce Q1 2026 Results

The latest update is out from Elite Pharmaceuticals ( ($ELTP) ). Elite Pharmaceuticals announced that it will release...

4M ago

ELTP

Elite Pharmaceuticals Reports Record Revenue Growth

Elite Pharmaceuticals (($ELTP)) has held its Q4 earnings call. Read on for the main highlights of the call....

5M ago

ELTP

Elite Pharmaceuticals Reports Strong Fiscal Year 2025 Results

Elite Pharmaceuticals ( ($ELTP) ) has released its Q4 earnings. Here is a breakdown of the information Elite...

5M ago

ELTP

Elite Pharmaceuticals files ANDA with FDA for central nervous system stimulant

Elite Pharmaceuticals announced the US Food and Drug Administration’s acceptance for review of an Abbreviated New Drug Application...

2y ago

ELTP

Elite Pharmaceuticals announces first shipment of generic Adderall XR to Prasco

Elite Pharmaceuticals announced the first shipment of generic Adderall XR to its distribution and marketing partner Prasco. Prasco...

2y ago

ELTP

Elite Pharmaceuticals appoints Carter Ward as CFO

Elite Pharmaceuticals announced the appointment of Carter Ward as its CFO, effective September 5, 2023. Ward previously served...

2y ago

ELTP

Elite Pharmaceuticals files ANDA with FDA for generic antimetabolite drug

Elite Pharmaceuticals announced earlier on Thursday, that it filed an Abbreviated New Drug Application, ANDA, with the US...

3y ago

ELTP

ELTP FAQ

What was Elite Pharmaceuticals’s price range in the past 12 months?

Elite Pharmaceuticals lowest stock price was $0.27 and its highest was $0.82 in the past 12 months.

What is Elite Pharmaceuticals’s market cap?

Elite Pharmaceuticals’s market cap is $653.39M.

When is Elite Pharmaceuticals’s upcoming earnings report date?

Elite Pharmaceuticals’s upcoming earnings report date is Feb 16, 2026 which is in 72 days.

How were Elite Pharmaceuticals’s earnings last quarter?

Elite Pharmaceuticals released its earnings results on Nov 14, 2025. The company reported $0.005 earnings per share for the quarter, beating the consensus estimate of N/A by $0.005.

Is Elite Pharmaceuticals overvalued?

According to Wall Street analysts Elite Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elite Pharmaceuticals pay dividends?

Elite Pharmaceuticals does not currently pay dividends.

What is Elite Pharmaceuticals’s EPS estimate?

Elite Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elite Pharmaceuticals have?

Elite Pharmaceuticals has 1,070,963,100 shares outstanding.

What happened to Elite Pharmaceuticals’s price movement after its last earnings report?

Elite Pharmaceuticals reported an EPS of $0.005 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -14.706%.

Which hedge fund is a major shareholder of Elite Pharmaceuticals?

Currently, no hedge funds are holding shares in ELTP

Elite Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

25.58%

Trailing 12-Months

Asset Growth

26.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Elite Pharmaceuticals

Elite Pharmaceuticals, Inc. (ELTP) is a specialty pharmaceutical company focused on the development and commercialization of innovative drug delivery systems and products. The company operates primarily in the pharmaceutical sector, with a focus on developing oral and injectable dosage forms. Elite Pharmaceuticals specializes in the formulation of generic and proprietary therapeutics, particularly in the areas of pain management, addiction, and other therapeutic categories, leveraging its advanced drug delivery technologies to enhance the bioavailability and efficacy of its products.

Elite Pharmaceuticals (ELTP) Earnings & Revenues

Historic Earnings Reports

ELTP Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Elite Pharmaceuticals reported strong revenue growth and improved operating profits, driven by increased market share and a robust product pipeline. However, increased competition has affected profit margins, and higher administrative costs have been noted. The company's balance sheet remains strong, but market dynamics could present challenges.View all ELTP earnings summaries